Bioethics

Preventing a post-antibiotic world

By Kevin Outterson Nick Bagley and I have an op-ed in today’s New York Times calling for serious economic incentives for antibiotics, delinking revenues from sales volumes with a $4 billion prize system. From the piece: On Friday, the Centers for Disease Control and Prevention released a disturbing report about the death of an elderly…

Published:

By Kevin Outterson

Nick Bagley and I have an op-ed in today’s New York Times calling for serious economic incentives for antibiotics, delinking revenues from sales volumes with a $4 billion prize system.

From the piece:

On Friday, the Centers for Disease Control and Prevention released a disturbing report about the death of an elderly woman in Washoe County, Nev. What killed her wasn’t heart disease, cancer or pneumonia. What killed her were bacteria that were resistant to every antibiotic doctors could throw at them.

This anonymous woman is only the latest casualty in a war against antibiotic-resistant bacteria — a war that we are losing. Although most bacteria die when they encounter an antibiotic, a few hardy bugs survive. Through repeated exposure, those tough bacteria proliferate, spreading resistance genes through the bacterial population. That’s the curse of antibiotics: The more they’re used, the worse they get, especially when they’re used carelessly. […]

Read more here.

 

About the author

  • Kevin Outterson

    Kevin Outterson has served as a guest blogger on Bill of Health. Kevin teaches health law and corporate law at Boston University, where he co-directs the Health Law Program. He serves as Editor-in-Chief of the Journal of Law, Medicine & Ethics; faculty co-advisor to the American Journal of Law & Medicine; immediate past chair of the Section on Law, Medicine & Health Care of the AALS; and a member of the Board of the American Society of Law, Medicine & Ethics. Before teaching, Kevin was a partner at two major US law firms.